CDTX News and Press, Cidara Therapeutics Inc. From 10/11/23

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious dise...

SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serio...

2023-09-22 19:48:58 ET Summary Janssen's decision to proceed with CD388 further de-risks Cidara Therapeutics (CDTX) and validates the potential of the Cloudbreak platform. Combined with impressive preclinical data by oncology candidates presented in the Virtual Research & Deve...

2023-09-15 15:00:00 ET More on the markets Key Region Of Support Sides With SPY Bullish Case Market Crosswinds And Nasdaq Looking Better Than Dow The Fed's rate-hike cycle has 'most assuredly ended' -- Lawrence Fuller Fund managers finally embrace U.S. stocks...

2023-09-14 10:51:26 ET More on Cidara Therapeutics Seeking Alpha’s Quant Rating on Cidara Therapeutics Cidara Therapeutics: Leveraging Antifungals To Move Into Cancer Therapy Cidara antifungal drug Rezzayo launched in US by partner Melinta For further ...

• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership following Election to Proceed notification • Detailed overview of potential role of Drug-Fc Conjugates (DFCs) in oncology; ...

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serio...

Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in milestones, plus royalties SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara ...

2023-08-16 08:18:35 ET Summary Cidara Therapeutics has recently gained FDA approval for rezafungin and is now focused on advancing its Cloudbreak platform in oncology and infectious disease indications, which has great potential. Potential revenue from rezafungin, CDTX's partnersh...

Dr. Davarpanah will lead Cidara’s oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX)...